MDxHealth SA (MDXH)
2.01
0.01 (0.50%)
At close: Jan 14, 2025, 3:59 PM
2.00
-0.50%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 0.8 |
| Market Cap | 99.49M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.55 |
| PE Ratio (ttm) | -1.3 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3.2 |
| Volume | 150,857 |
| Avg. Volume (20D) | 136,763 |
| Open | 2.05 |
| Previous Close | 2.00 |
| Day's Range | 1.98 - 2.08 |
| 52-Week Range | 1.55 - 4.44 |
| Beta | undefined |
About MDXH
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use ...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Nov 4, 2021
Employees 300
Stock Exchange NASDAQ
Ticker Symbol MDXH
Website https://mdxhealth.com
Analyst Forecast
According to 2 analyst ratings, the average rating for MDXH stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 248.26% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
MDxHealth SA is scheduled to release its earnings on Feb 26, 2025,
during market hours.
Analysts project revenue of $23.08M, reflecting a 18.98% YoY growth and earnings per share of -0.2, making a -48.72% decrease YoY.
Analysts project revenue of $23.08M, reflecting a 18.98% YoY growth and earnings per share of -0.2, making a -48.72% decrease YoY.
3 months ago ·
Source
-21.26%
MDxHealth shares are trading lower after the compa...
Unlock content with
Pro Subscription
3 months ago ·
Source
+0.79%
MDxHealth shares are trading lower after the company announced the launch of a $40 million offering of ordinary shares.
